{"url_path":"/sec/zbio/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059735-index.html","accession_number":"0001104659-26-059735","cik":"0001953926","ticker":"ZBIO","issuer_name":"Zenas BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059735-index.html","primary_entity_key":"0001953926","primary_entity_name":"Zenas BioPharma, Inc."},"word_count":65,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\n**(b) Use of Proceeds from Public Offering of Common Stock**\n\nOn September 16, 2024, the Company’s registration statement on Form S-1 (File No.333-281713)  (the “IPO Prospectus”) relating to our IPO became effective.\n\nThere has been no material change in the planned use of proceeds from our IPO from that described in the IPO Prospectus."}